Company intelligence / Profile preview

Cellonis Biotechnologies

Beijing, Beijing, Chinaprnewswire.com ↗
Ownership
Private
Development stage
Commercial
01

Overview

Cellonis Biotechnologies has conducted Phase 1 clinical trials for stem cell therapies targeting diabetes and has reported successful treatment of a glioma (brain cancer) in a Norwegian patient using their stem cell-based therapy.

Therapeutic areas
OncologyEndocrinology
Modalities
Stem Cell TherapyImmunotherapy
Industry
Biotech
02

Drug pipeline

1 asset

mesenchymal stem cells (Cellonis Biotechnologies)

Unknown

Beyond the preview

Go deeper on Cellonis Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellonis Biotechnologies.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call